RARA and acute promyelocytic leukemia: The use of synthetic derivatives of all-trans retinoic acid (ATRA) that specifically block the inhibitory effect of RARα on CMA process without affecting its transcriptional program makes cells more resistant to oxidative stress and proteotoxicity, which could have a real impact, especially in hematopoietic malignancies and, more particularly, in APL [101].